https://orcid.org/0000-0002-1019-0413
References
- United States Drug Enforcement Administration. DEA reduces amount of opioid controlled substances to be manufactured in 2017; October 4, 2016. Available from: https://www.dea.gov/press-releases/2016/10/04/dea-reduces-amount-opioid-controlled-substances-be-manufactured-2017. Accessed September 15, 2020.
- United States Drug Enforcement Administration. DEA proposes reduction to amount of controlled substances to be manufactured in 2018; August 4, 2017. Available from: https://www.dea.gov/press-releases/2017/08/04/dea-proposes-reduction-amount-controlled-substances-be-manufactured-2018. Accessed September 15, 2020.
- United States Drug Enforcement Administration. Justice Department, DEA propose significant opioid manufacturing reduction in 2019; August 16, 2019. Available from: https://www.dea.gov/press-releases/2018/08/16/justice-department-dea-propose-significant-opioid-manufacturing-reduction. Accessed September 15, 2020.
- United States Drug Enforcement Administration. DEA proposes to reduce the amount of five opioids manufactured in 2020, marijuana quota for research increases by almost a third; September 11, 2019. Available from: https://www.dea.gov/press-releases/2019/09/11/dea-proposes-reduce-amount-five-opioids-manufactured-2020-marijuana-quota. Accessed September 28, 2020.
- United States Drug Enforcement Administration. Adjustments to aggregate production quotas for certain schedule II controlled substances and assessment of annual needs for the list i chemicals ephedrine and pseudoephedrine for 2020, in response to the coronavirus disease 2019 public health emergency; April 10, 2020. Available from: https://www.deadiversion.usdoj.gov/fed_regs/quotas/2020/fr0410.htm. Accessed September 28, 2020.
- Girion L, Levine D, Respaut R.Special report: COVID deepens the other opioid crisis – a shortage of hospital painkillers. Reuters healthcare & pharma; June 9,2020. Available from:https://www.reuters.com/article/us-health-coronavirus-opioids-specialrep/special-report-covid-deepens-the-other-opioid-crisis-a-shortage-of-hospital-painkillers-idUSKBN23G1GM. Accessed October 6,2020.
- United States Drug Enforcement Administration. Proposed aggregate production quotas for schedule i and ii controlled substances and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine for 2021; September 1, 2020. Available from: https://www.federalregister.gov/documents/2020/09/01/2020-19285/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of. Accessed September 28, 2020.
- Bruera E. Parenteral opioid shortage - treating pain during the opioid-overdose epidemic. N Engl J Med. 2018;379(7):601–603. doi:10.1056/NEJMp1807117
- Hollingsworth H, Herndon C. The parenteral opioid shortage: causes and solutions. J Opioid Manag. 2018;14(2):81–82. doi:10.5055/jom.2018.0434
- Haider A, Qian Y, Lu Z, et al. Implications of the parenteral opioid shortage for prescription patterns and pain control among hospitalized patients with cancer referred to palliative care. JAMA Oncol. 2019;5(6):841–846. doi:10.1001/jamaoncol.2019.0062
- Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–624. doi:10.1016/S0025-6196(11)60750-7
- Dalal S, Bruera E. Pain management for patients with advanced cancer in the opioid epidemic era. Am Soc Clin Oncol Educ Book. 2019;39:24–35.
- Wang B, Downing NL. A crisis within an epidemic: critical opioid shortage in US hospitals. Postgrad Med J. 2019;95(1127):515–516. doi:10.1136/postgradmedj-2018-136058
- Terry NP. The opioid litigation unicorn. SC Law Rev. 2019;70:637–666.
- Reardon CE, Kane-Gill SL, Smithburger PL, Dasta JF. Sufentanil sublingual tablet: a new option for acute pain management. Ann Pharmacother. 2019;53(12):1220–1226. doi:10.1177/1060028019863144
- Kim DE, Pruskowski KA, Ainsworth CR, Linsenbardt HR, Rizzo JA, Cancio LC. A review of adjunctive therapies for burn injury pain during the opioid crisis. J Burn Care Res. 2019;40(6):983–995. doi:10.1093/jbcr/irz111
- Salajegheh R, Nemergut EC, Rice TM, et al. Impact of a perioperative oral opioid substitution protocol during the nationwide intravenous opioid shortage: a single center, interrupted time series with segmented regression analysis. PLoS One. 2020;15(6):e0234199. doi:10.1371/journal.pone.0234199
- Tran KK, VanDaele MA, Tran S, Stevens SA, Maltese Dietrich N, Franck AJ. Evaluation of acute postoperative pain management during an injectable opioid shortage. Ann Pharmacother. 2020;1060028020962037. doi:10.1177/1060028020962037
- Franz AM, Dahl JP, Huang H, et al. The development of an opioid sparing anesthesia protocol for pediatric ambulatory tonsillectomy and adenotonsillectomy surgery-A quality improvement project. Paediatr Anaesth. 2019;29(7):682–689. doi:10.1111/pan.13662
- Barnes TA, Feng HX, Herrera NA, Leathers LA. The impact of intravenous opioid shortages on postoperative pain control in a pediatric cardiac intensive care unit. J Card Surg. 2020;35(4):840–844. doi:10.1111/jocs.14492
- Cheng B. Disparities in access to palliative medication: the duty of the state to ensure opioid medication access. Penn Bioeth J. 2018;8(2):10–14.
- United States Drug Enforcement Administration. Registrant Actions; 2020. Available from: https://www.deadiversion.usdoj.gov/fed_regs/actions/2020/index.html. Accessed September 28, 2020.